Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000233542 | SCV000288564 | benign | Wilms tumor 1 | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002503909 | SCV002807258 | likely benign | Wilms tumor 1; Simpson-Golabi-Behmel syndrome type 1 | 2021-09-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003278710 | SCV003962719 | likely benign | Inborn genetic diseases | 2023-04-19 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV003437023 | SCV004165652 | likely benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | GPC3: BS2 |
Prevention |
RCV003929970 | SCV004754000 | likely benign | GPC3-related disorder | 2020-12-01 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |